<DOC>
	<DOCNO>NCT00480688</DOCNO>
	<brief_summary>To assess immunogenicity M. bovis BCG , give intrademally standard dose use clinical practice measure development immune response first six month administration . M. bovis BCG fully license vaccine routine clinical use last 50 year . It widely administer vaccine world today excellent safety record .</brief_summary>
	<brief_title>A Study Immunogenicity M. Bovis BCG , Delivered Intradermally Healthy Volunteers</brief_title>
	<detailed_description>Volunteers study recruited advertisement . Each volunteer receive information sheet concern study agree participate writing . Volunteers give least 48 hour read information leaflet agree participate . Female volunteer pregnancy test prior enrollment . Volunteers give sign consent GP â€™ notify participation trial . The GP faxed letter day screen ask reply know reason volunteer take part . The signed consent form also faxed letter .</detailed_description>
	<criteria>Healthy adult age 1865 year . Normal medical history physical examination . Normal urine dipstick , blood count , liver enzymes , creatinine . Exposure TB/BCG vaccination point . Previous residence TB endemic area . Clinically significant history skin disorder ( eczema , psoriasis , etc . ) , allergy , immunodeficiency , cardiovascular disease , respiratory disease , endocrine disorder , liver disease , renal disease , gastrointestinal disease , neurological illness , psychiatric disorder , drug alcohol abuse . Oral systemic steroid medication use immunosuppressive agent . Positive HIV core HBV antibody test . Positive Heaf test Positive ANA serum antiDNA antibody . Confirmed pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>TB</keyword>
	<keyword>BCG</keyword>
</DOC>